Annual report and quarterly report revealed the close, A-share dividends and buyback data were released. Under the background of "heavy shareholder return", the repurchase of dividends in the pharmaceutical industry has increased significantly, and Yao Ming Kant has made 48.Freespinnodeposit2022820 million yuan topped the list.

Yao Ming KantFreespinnodeposit2022Shareholders reaped a rich harvest in 2023.Freespinnodeposit2022In return. Yao Ming Kant not only has steady performance growth, but also has passed as high as 28%.Freespinnodeposit2022The cash dividend of .82 billion yuan allows shareholders to share the fruits of the company's development. This dividend measure based on performance growth not only strengthens investor confidence, but also demonstrates Yao Ming Kant's adherence to shareholder value.

Yao Ming Kant's dividend measure is a direct feedback to its growing performance. Yao Ming Kant's revenue and net profit reached record highs in 2023, which can not be achieved without the long-term trust and support of shareholders. Therefore, Yao Ming Kant returns the company's growth dividend to shareholders by way of cash dividend, which is not only a return to shareholders, but also the embodiment of their social responsibility.

Yao Ming Kant's shareholder feedback also reflects the company's firm confidence in the future development, through continuous innovation and optimal management, to ensure the sustained and healthy development of the company and bring more rich returns for shareholders.